Quince Therapeutics Webinar to Address Ataxia-Telangiectasia Needs

Author: Dylan Bailey Updated: 01-28-2025 09:05 AM

Upcoming Webinar on Ataxia-Telangiectasia by Quince Therapeutics

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company committed to utilizing the unique power of a patient’s own biology, is set to host a virtual investor webinar dedicated to the urgent unmet needs associated with Ataxia-Telangiectasia (A-T). This significant event is scheduled for February 7, 2025, beginning at 10:00 a.m. Eastern Time.

Expert Insights on A-T

During the webinar, attendees will gain valuable insights from Dr. Mary Kay Koenig, a recognized leader in A-T research. Dr. Koenig is expected to cover several key topics, including: an overview of A-T's natural history, current treatment strategies, an analysis of the competitive therapeutic landscape, and details on Quince’s Phase 3 clinical trial of EryDex for A-T treatment. Additionally, Dirk Thye, M.D., who serves both as the Chief Executive Officer and Chief Medical Officer at Quince, will participate to share a comprehensive update on the company, including insights on ongoing clinical trials.

Recognized Leadership in Pediatric Neurodegenerative Disorders

Dr. Mary Kay Koenig brings a wealth of knowledge and experience to the table. As a board-certified child neurologist specializing in various neurodegenerative conditions, her role at the McGovern Medical School at the University of Texas in Houston emphasizes advancing research and clinical care for children affected by genetic disorders. Dr. Koenig's dedication to mentoring future medical professionals also speaks volumes about her commitment to the field.

Register and Participate

Those interested in this informative webinar can register through Quince's official channels. A live broadcast of the event will be accessible on Quince’s Events page, allowing participants to engage with the content comprehensively. Following the event, an archived recording will be available for those who may want to revisit the discussions at a later time.

About Quince Therapeutics

Quince Therapeutics, Inc. (Nasdaq: QNCX) is dedicated to pioneering approaches to treating rare diseases by leveraging the intrinsic biology of the patient. Their mission to provide innovative therapies is reflected in their robust clinical pipeline. For further information regarding their initiatives, visit their official website and engage with them on various social media platforms.

Frequently Asked Questions

What is the main focus of the Quince Therapeutics webinar?

The webinar will address the high unmet need in the treatment of Ataxia-Telangiectasia.

Who is Dr. Mary Kay Koenig?

Dr. Koenig is a board-certified child neurologist specializing in neurodegenerative disorders, providing crucial insights for the webinar.

When is the webinar scheduled?

The webinar is set for February 7, 2025, at 10:00 a.m. Eastern Time.

How can I register for the webinar?

Participants can register for the webinar by visiting Quince Therapeutics' official website and following the registration link.

What will Dr. Koenig discuss during the event?

She will cover A-T’s natural history, treatment approaches, and details on the Phase 3 clinical trial of EryDex.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.